	Des Atouts		Date
Acadia Pharmaceuticals	USD 1.33B	105.22M	2025-09
Agios Pharmaceuticals	USD 1.3B	88.48M	2025-12
Alnylam Pharmaceuticals	USD 4.97B	114.67M	2025-12
BioCryst Pharmaceuticals	USD 446.42M	10.76M	2025-09
BioMarin Pharmaceutical	USD 7.59B	20.85M	2025-12
Esperion Therapeutics	USD 364.02M	16.93M	2025-09
Immunic	USD 40.7M	20.72M	2025-09
Insmed	USD 2.26B	96.18M	2025-12
Ionis Pharmaceuticals	USD 3.03B	47.96M	2025-09
Karyopharm Therapeutics	USD 96.23M	8.65M	2025-09
Kyowa Hakko Kirin	JPY 1.11T	30.41B	2025-12
MacroGenics	USD 270.76M	25.34M	2025-09
Moderna	USD 12.34B	203M	2025-12
Neurocrine Biosciences	USD 4.63B	365.8M	2025-12
PTC Therapeutics	USD 2.9B	255.07M	2025-12
Puma Biotechnology	USD 202.86M	7.95M	2025-09
Regeneron Pharmaceuticals	USD 40.56B	389.3M	2025-12
Sarepta Therapeutics	USD 3.49B	186.38M	2025-09
Ultragenyx Pharmaceutical	USD 1.53B	341.56M	2025-12
Vertex Pharmaceuticals	USD 25.64B	780.7M	2025-12
Xoma	USD 263.15M	39.7M	2025-09

Ultragenyx Pharmaceutical Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.